RIPK1 and sarcoma: To evaluate the possibility of harnessing RIPK1's cytotoxic and immunogenic potential during ILP‐based and TNF‐mediated treatments in combination with SM, we employed a syngeneic, immune‐competent rat model of ILP‐TNF/Mel using the syngeneic BN175 sarcoma cell line in Brown Norway rats (Pencavel et al, 2015; Wilkinson et al, 2016).